Eduarda P. Martins

Dr. Eduarda P. Martins

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 June 2025 in Scientific Data
Verified
Journal Article
Open access
PDF file
MMMónica Leiria de Mendonça
Mónica Leiria de Mendonça
RCRoberta Coletti
Roberta Coletti
CGCéline S. Gonçalves
Céline S. Gonçalves
EMEduarda P. Martins
Eduarda P. Martins
BCBruno Costa
Bruno Costa
MLMarta Lopes
Marta Lopes
The understanding of glioma disease has significantly advanced through the application of genetic and molecular profiling techniques on brain tumour tissue. Molecular biomarkers have gained a crucial role in glioma diagnosis, driving groundbreaking changes in the disease classification as standardised by the 2016 and 2021 World Health Organisation (WHO) Classification of Tumours of the Central Nervous System. Recent insights from large-scale multi-omics databases, such as The Cancer Genome Atlas (TCGA), have enriched our comprehension of this cancer type. However, given the evolution of glioma classification, retrospective databases may contain outdated annotations, suboptimal for research. To address this issue, we propose two methods for updating the tumor classification of TCGA glioma samples according to the 2016 and 2021 WHO guidelines, through the integration of open-access curated molecular profiling data. Respectively, our Method-2016 and Method-2021 allowed for the diagnostic update of 98% and 87% of cases. The proposed reclassification pipelines, provided in R scripts, enable straightforward reproduction or customisation upon new WHO guideline releases.

10 January 2020 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
Céline GonçalvesCéline Gonçalves
Céline Gonçalves
AXAna Xavier‐Magalhães
Ana Xavier‐Magalhães
EMEduarda P. Martins
Eduarda P. Martins
APAfonso A. Pinto
Afonso A. Pinto
MPManuel Melo Pires
Manuel Melo Pires
BCBruno Costa
Bruno Costa
Despite much effort to improve treatments, patients with malignant glioma still present a very poor prognosis that has not changed significantly in the last decades. In this context, it is crucial to better understand glioma pathogenesis to identify new molecular prognostic subgroups and therapeutic targets. WNT6 was recently identified as a new oncogenic molecule in glioblastoma (GBM), with prognostic value in patients, but the mechanisms underlying WNT6 aberrant expression in glioma are still unknown. WNT6 was overexpressed in a subset of gliomas independently of IDH mutations, 1p/19q codeletion status, and WNT6 gene copy number. Interestingly, WNT6 expression is associated with the DNA methylation levels of particular CpG regions at both the WNT6 promoter and the gene body in glioma patient samples. HOXA9, a transcription factor previously associated with poorer clinical outcome in GBM, was identified as a novel transcriptional regulator of WNT6, activating the WNT/β‐catenin pathway in vitro and in vivo. In various cohorts of glioma patients, mRNA levels of WNT6 and HOXA9 were significantly correlated, extending our in vitro and in vivo findings into the clinical setting. Interestingly, this novel molecular link between WNT6 and HOXA9 was not limited to glioma, as they were co‐expressed also in patients with other tumor types. Clinically, WNT6 was a prognostic biomarker of shorter survival in GBM, independently of HOXA9 expression. Concomitant high expression of both WNT6 and HOXA9 identified a subgroup of patients with particularly dismal survival. These findings describe novel WNT6 regulatory mechanisms in GBM, establishing particular DNA methylation patterns and HOXA9 as critical regulators of WNT6 expression in glioma. This HOXA9‐WNT6 molecular link supports WNT signaling in GBM cells and is a powerful prognostic biomarker, highlighting the clinical relevance of this axis in patients. Novel therapies targeting WNT6‐HOXA9 signaling may thus be useful for this deadly disease.

17 December 2021 in Molecular Oncology
Verified
Journal Article
Open access
PDF file
EMEduarda P. Martins
Eduarda P. Martins
Céline GonçalvesCéline Gonçalves
Céline Gonçalves
MPMarta Pojo
Marta Pojo
RCRita Carvalho
Rita Carvalho
ARAna S. Ribeiro
Ana S. Ribeiro
BCBruno Costa
Bruno Costa
Glioblastoma (GBM) is the most common and malignant primary brain tumor in adults. The prognosis of patients is very poor, with a median overall survival of ~ 15 months after diagnosis. Cadherin‐3 (also known as P‐cadherin), a cell–cell adhesion molecule encoded by the CDH3 gene, is deregulated in several cancer types, but its relevance in GBM is unknown. In this study, we investigated the functional roles, the associated molecular signatures, and the prognostic value of CDH3/P‐cadherin in this highly malignant brain tumor. CDH3/P‐cadherin mRNA and protein levels were evaluated in human glioma samples. Knockdown and overexpression models of P‐cadherin in GBM were used to evaluate its functional role in vitro and in vivo. CDH3‐associated gene signatures were identified by enrichment analyses and correlations. The impact of CDH3 in the survival of GBM patients was assessed in independent cohorts using both univariable and multivariable models. We found that P‐cadherin protein is expressed in a subset of gliomas, with an increased percentage of positive samples in grade IV tumors. Concordantly, CDH3 mRNA levels in glioma samples from The Cancer Genome Atlas (TCGA) database are increased in high‐grade gliomas. P‐cadherin displays oncogenic functions in multiple knockdown and overexpression GBM cell models by affecting cell viability, cell cycle, cell invasion, migration, and neurosphere formation capacity. Genes that were positively correlated with CDH3 are enriched for oncogenic pathways commonly activated in GBM. In vivo, GBM cells expressing high levels of P‐cadherin generate larger subcutaneous tumors and cause shorter survival of mice in an orthotopic intracranial model. Concomitantly, high CDH3 expression is predictive of shorter overall survival of GBM patients in independent cohorts. Together, our results show that CDH3/P‐cadherin expression is associated with aggressiveness features of GBM and poor patient prognosis, suggesting that it may be a novel therapeutic target for this deadly brain tumor.

2 March 2021 in Cancers
Verified
Journal Article
Open access
PDF file
MLMarta Lopes
Marta Lopes
EMEduarda P. Martins
Eduarda P. Martins
Susana VingaSusana Vinga
Susana Vinga
BCBruno Costa
Bruno Costa
Network science has long been recognized as a well-established discipline across many biological domains. In the particular case of cancer genomics, network discovery is challenged by the multitude of available high-dimensional heterogeneous views of data. Glioblastoma (GBM) is an example of such a complex and heterogeneous disease that can be tackled by network science. Identifying the architecture of molecular GBM networks is essential to understanding the information flow and better informing drug development and pre-clinical studies. Here, we review network-based strategies that have been used in the study of GBM, along with the available software implementations for reproducibility and further testing on newly coming datasets. Promising results have been obtained from both bulk and single-cell GBM data, placing network discovery at the forefront of developing a molecularly-informed-based personalized medicine.

16 February 2021 in Cancers
Verified
Journal Article
Open access
PDF file
JCJoana Vieira de Castro
Joana Vieira de Castro
Céline GonçalvesCéline Gonçalves
Céline Gonçalves
EMEduarda P. Martins
Eduarda P. Martins
IMIrene Miranda-Lorenzo
Irene Miranda-Lorenzo
MCMariana T. Cerqueira
Mariana T. Cerqueira
BCBruno Costa
Bruno Costa
The identification of cancer stem cells (CSCs), which are implicated in tumor initiation, progression, therapy resistance, and relapse, is of great biological and clinical relevance. In glioblastoma (GBM), this is still a challenge, as no single marker is able to universally identify populations of GBM cancer stem cells (GSCs). Indeed, there is still controversy on whether biomarker-expressing cells fulfill the functional criteria of bona fide GSCs, despite being widely used. Here, we describe a novel subpopulation of autofluorescent (Fluo+) cells in GBM that bear all the functional characteristics of GSCs, including higher capacity to grow as neurospheres, long-term self-renewal ability, increased expression of stem cell markers, and enhanced in vivo tumorigenicity. Mechanistically, the autofluorescent phenotype is largely due to the intracellular accumulation of riboflavin, mediated by the ABC transporter ABCG2. In summary, our work identifies an intrinsic cellular autofluorescent phenotype enriched in GBM cells with functional stem cells features that can be used as a novel, simple and reliable biomarker to target these highly malignant tumors, with implications for GBM biological and clinical research.

19 January 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EMEduarda P. Martins
Eduarda P. Martins
JCJoana Vieira de Castro
Joana Vieira de Castro
RFRita Fontes
Rita Fontes
SMSara Monteiro-Reis
Sara Monteiro-Reis
Rui HenriqueRui Henrique
Rui Henrique
BCBruno Costa
Bruno Costa
The long non-coding RNA HOX transcript antisense intergenic RNA (HOTAIR) is associated with oncogenic features in bladder cancer and is predictive of poor clinical outcomes in patients diagnosed with this disease. In this study, we evaluated the impact of the HOTAIR single nucleotide polymorphisms rs920778 and rs12826786 on bladder cancer risk and survival. This case-control study included 106 bladder cancer patients and 199 cancer-free controls. Polymorphisms were evaluated through PCR-restriction fragment length polymorphism. The odds ratio and 95% confidence intervals were tested using univariable and multivariable logistic regressions. The effects on patient survival were evaluated using the log-rank test and Cox regression models. Our data showed that the HOTAIR rs920778 and rs12826786 genetic variants are not associated with the risk of developing bladder cancer. Nevertheless, survival analyses suggested that the HOTAIR rs920778 TT genotype and rs12826786 CC genotype are associated with increased survival in male bladder cancer patients and in patients, both male and female, who have primary tumors with a pathological stage of pT2. Together, these results suggest that, despite not being associated with bladder cancer risk, HOTAIR rs920778 and rs12826786 polymorphisms might represent new prognostic factors in this type of cancer. This is particularly important as these polymorphisms might be easily evaluated in bladder cancer patients in a minimally invasive manner to better predict their clinical outcomes.